For ovarian cancer, mutations in the homologous recombination (HR) repair genes BRCA1 and BRCA2 are the most common alterations and inhibitions of the DDR pathway protein poly(ADP ribose) polymerase (PARP). This evidence concerns the gene BRCA2 and ovarian cancer.